Status:
COMPLETED
Tirofiban in Stenting for Long Coronary Lesion
Lead Sponsor:
Shanghai Jiao Tong University School of Medicine
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
Periprocedural myonecrosis or infarction are associated with short, intermediate, and long term adverse outcomes. Previous study indicated 12.6% of patients suffered a peri-procedural CK-MB rise by ov...
Detailed Description
According to the results of 12.6% occurrence of peri-procedural myocardial infarction after long stent implantation by previous report\[International Journal of Cardiology 2009;134: 231-237\], the inv...
Eligibility Criteria
Inclusion
- Age between 18y\~80y, with symptomatic coronary disease
- At least one lesion length more than 40mm to be treated by overlapping drug-eluting stents in major epicardial coronary vessel
Exclusion
- Aspirin or clopidogrel intolerance
- Lesions length less than 40mm, or overlapping stent length less than 40mm
- Bifurcation lesions need to be treated by two stents
- Patients with acute coronary syndrome and elevated baseline cardiac enzyme (CK-MB)
- Left ventricular ejection fraction less than 0.35
- Baseline estimated GFR less than 30
- Estimated life time less than one year
- Refuse to sign the informed consent
Key Trial Info
Start Date :
November 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2014
Estimated Enrollment :
748 Patients enrolled
Trial Details
Trial ID
NCT01498003
Start Date
November 1 2011
End Date
June 1 2014
Last Update
July 14 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China, 200025